Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Maria Di Bartolomeo et al.|The Lancet Oncology|2021Cited by 411
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Yasuyuki Kawamoto et al.|Nature Medicine|2020Cited by 366
Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a second‐line treatment for Japanese patients with metastatic colorectal cancerTadamichi Denda, Takayuki Yoshino, Daisuke Sakai et al.|Cancer Science|2019Cited by 39
A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroupAkira Kawai, Nobuaki Fukasawa, Nobuhito Araki et al.|Japanese Journal of Clinical Oncology|2016Cited by 38